Initial Results With IMA402, a PRAME-Targeted T-cell Receptor (TCR)- based Bispecific T-cell Engager (TCER) in Advanced Solid Tumors
Schadendorf, et al.
Read more
Response Durability With Anzutresgene Autoleucel (Anzu-cel), a PRAME-directed T-cell Receptor T-cell Therapy, in Advanced Melanoma
Alsdorf, et al.
Read more
Targeting PRAME+ Tumors with IMA203CD8, a PRAME-directed TCR T-cell Therapy: Results from a Phase 1 Study
Busse, et al.
Read more